Compare iShares Core US Aggregate Bond ETF (AGG) vs IDEXX Laboratories, Inc. (IDXX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares Core US Aggregate Bond ETF vs IDEXX Laboratories, Inc. — how do they compare? iShares Core US Aggregate Bond ETF trades at $97.52, while IDEXX Laboratories, Inc. trades at $574.29 (market cap $46.22B). The key difference: IDEXX Laboratories, Inc. is trading nearer its 52-week high, iShares Core US Aggregate Bond ETF nearer its low. Which is the better fit depends on your goals.
| AGG | IDXX | |
|---|---|---|
Sector | Fixed Income | Health |
52-Week High | $101.40 | $766.68 |
52-Week Low | $97.24 | $526.44 |
Market Cap | — | $46.22B |
Enterprise Value | — | $47.12B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AGG trades at $97.505, up 0.27% on the day, with a bearish technical signal from moving averages and neutral oscillators. Recent news highlights institutional activity, including Bay Colony Advisory reducing holdings and First Bank & Trust increasing its stake. Bond ETF flows remain strong, with $300 billion in H1 2026 inflows, but rising Treasury yields and inflation concerns pressure fixed-income assets.
The outlook is cautious due to bearish technicals and macroeconomic headwinds like higher yields and oil prices. Risks include Fed rate hike expectations and Middle East tensions, but AGG offers steady dividends and remains a core holding for income-focused portfolios amid market volatility.
IDEXX Laboratories (IDXX) trades at $595.76, up 1.55% on the day, with a bullish technical signal and strong fundamental performance. Recent Q2 2026 earnings beat expectations with EPS of $4.27 versus $3.94 expected, driven by 9% organic revenue growth. The company raised full-year EPS guidance to $14.69–14.94, reflecting robust demand in companion animal diagnostics. Valuation ratios remain elevated with a P/E of 41.23, supported by high profitability margins including a net income margin of 25.03% and ROE of 74.21%.
Outlook is positive given consistent earnings beats, international expansion, and product innovation, but risks include premium valuation sensitivity and competitive pressures. The consensus price target of $683.33 implies 14.7% upside, with 57% of analysts rating it Buy. Investors should weigh growth durability against high multiples.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares Core US Aggregate Bond ETF
AGG tracks the Bloomberg U.S. Aggregate Bond Index, providing broad exposure to the total U.S. investment-grade bond market. It serves as a core portfolio building block by diversifying across Treasuries, government-related bonds, corporate debt, and mortgage-backed securities.
Read more on AGG →About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →
